Medtronic Financial News

Reliance Industries (RIL) has appointed Ira Bindra as group president, responsible for people, leadership, and talent management at the oil-to-retail conglomerate. She is the first non-family woman and the youngest member to join Reliance's executive committee, marking a strategic shift in the company's approach to organisational transformation. Bindra joins Reliance from Medtronic, US, where she was head of human resources and vice president for global regions. Her appointment was announced directly by chairman Mukesh Ambani, an unusual step for a company where senior functional heads typically make such announcements. «Ira Bindra is a global HR and business leader with deep domain expertise across industries, geographies, and business cycles,» Ambani said in an internal organisational announcement reviewed by ET. «She has led large HR teams in Fortune 100 companies and successfully executed bold business transformations, from designing new operating models and creating new business lines to managing significant divestitures.»

Mukesh Ambani, the richest Asian, has announced the appointment of Ira Bindra as the new Group President of entire people, leadership and talent piece at Reliance Industries Ltd as he looks to pivot people policies at the oil-to-telecom conglomerate. Normally, its functional heads who make announcements on talent hiring at senior level and Bindra is the first in recent times whose appointment has been announced by Ambani, chairman and managing director of Reliance, himself. She has been hired to drive transformation across the entire organisation. With her appointment, HR transformation at an unprecedented level is expected at Reliance. «Bindra joins us from Medtronic, USA, where she was the Head of Human Resources & Vice President — Global Regions,» Ambani said in an internal organisation announcement.

Dexcom shares closed more than 40% lower on Friday after the glucose monitor maker slashed its annual revenue forecast due to the fallout from a salesforce revamp, prompting some analysts to question its long-term prospects. The company's shares closed at a four-year low of $64, wiping out $25.45 billion from its market value.

recalled by Health Canada, including one the agency warns could potentially cause death in the most vulnerable patients.That device is known as the OmniLab Advanced, and it’s typically used by people with sleep apnea — a condition where those affected stop and restart breathing while asleep.According to the recall notice, the OmniLab Advanced has an alarm to notify users when the device’s ventilator finds an internal error or problem. The agency says products with any lot are recalled or have the model number 1044278.According to the agency, this includes the device rebooting intermittently, restarting therapy, or even entering an inoperative state with or without reboots.Health Canada says any of the issues could “result in interruption and/or loss of therapy which may lead to hypoventilation, mild to severe hypoxemia, hypercarbia, respiratory failure/insufficiency, or potentially death in the most vulnerable patients.”It’s not the only medical device recalled, however.Among the recalls, several of which began last month, are multiple Medtronic cannulae products.

medical device maker Medtronic, which gave the world the first battery-powered pacemaker seven decades ago, is betting big on India. Geoff Martha, its chairman and CEO, told Viswanath Pilla in an interview that Medtronic's next phase of growth in the country will involve evaluating possibilities of redesigning products to make them more affordable for patients, sourcing components locally, and manufacturing in India. Edited excerpts: How are you planning to achieve Medtronic's goal of reaching 1 billion patients every year? We reach two patients every second and we're very proud of it. But 80 million people is a fraction of the world's population… With these digital technologies coming in, I think that'll allow us to access so many more patients. Because it's going to personalise these therapies, lower the cost. So that's the aspiration that we need to map our strategy to get to 1 billion a year.

Prosecutors say an executive at a medical device company has been convicted in Minnesota of insider trading for a scheme involving negotiations for the acquisition of the firm that was valued at $1.6 billion

Stocks that are trading heavily or have substantial price changes on Tuesday: Enpro, Axsome Therapeutics fall; Walmart, Medtronic rise

By Khushi Mandowara and Christy Santhosh

Investing.com — Medtronic (NYSE:MDT) has raised its annual revenue and earnings outlook following «broad-based, diversified» growth across several of the medical device manufacturer's businesses in its fiscal second quarter.

In a recent financial analysis, Whitbread (LON:WTB), known for its hospitality brands, has demonstrated financial efficiency with a return on capital employed (ROCE) of 7.2%, which is in line with the industry average of 7.0%. This performance metric is crucial as it indicates how effectively a company is generating profits from its capital.

Medtronic is seeking to streamline its portfolio and focus on its higher-growth assets, such as its heart and diabetes devices, by divesting the two units which generated approximately $2.2 billion in revenue in the 2022 fiscal year according to the company. The businesses that Medtronic would shed would be moved to a new company majority-owned by Carlyle, the sources said. Medtronic would retain a stake in the new company of more than 35%, the sources added.

Investing.com -- Shares in Medtronic PLC (NYSE:MDT) fell in early trading on Thursday after a regulatory panel in the U.S. voted against recommending the use of its blood pressure treatment device.

In this article

In this article

In this article

Take a look at some of the biggest movers in the premarket:

In this article

In this article

In this article

In this article

In this article